Regencell Bioscience Holdings Limited(RGC)Earnings, Financials & Key Ratios
RGC•NASDAQ
$27.59
$13.64B mkt cap·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Show more
- Revenue$0
- EBITDA-$4M+27.5%
- Net Income-$4M+26.7%
- EPS (Diluted)-0.01+26.9%
- ROE-42.58%-5.4%
- ROIC-43.77%-3.8%
- Debt/Equity0.01-73.0%
RGC Key Insights
Regencell Bioscience Holdings Limited (RGC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 1659.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RGC Price & Volume
Regencell Bioscience Holdings Limited (RGC) stock price & volume — 10-year historical chart
Loading chart...
RGC Growth Metrics
Regencell Bioscience Holdings Limited (RGC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM58.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-565.15%
Return on Capital
10 Years-1001.51%
5 Years-1001.51%
3 Years-67.56%
Last Year-46.76%
RGC Recent Earnings
Regencell Bioscience Holdings Limited (RGC) EPS & revenue vs analyst estimates — last 4 quarters
Q4 2025Latest
Nov 18, 2025EPS
$0.00
Revenue
—
Q3 2025
Jun 26, 2025EPS
$0.14
Revenue
—
Q1 2025
Jan 24, 2025EPS
$0.14
Revenue
—
Q1 2024
Jan 26, 2024EPS
$0.00
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 18, 2025 | $0.00 | — |
| Q3 2025 | Jun 26, 2025 | $0.14 | — |
| Q1 2025 | Jan 24, 2025 | $0.14 | — |
| Q1 2024 | Jan 26, 2024 | $0.00 | — |
Based on last 10 quarters of dataView full earnings history →
RGC Peer Comparison
Regencell Bioscience Holdings Limited (RGC) competitors in Traditional Chinese medicine producers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACMR | 3.67B | 55.38 | 40.42 | 15.24% | 10.44% | 6.11% | 0.16 | |
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 |
Compare RGC vs Peers
Regencell Bioscience Holdings Limited (RGC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RGC Income Statement
Regencell Bioscience Holdings Limited (RGC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | 100% |
| Cost of Goods Sold | 0 | 9.52K | 26.46K | 604.4K | 769.69K | 745.59K | 769.69K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -9.52K▲ 0% | -26.46K▼ 178.0% | -604.4K▼ 2184.5% | -769.69K▼ 27.3% | -745.59K▲ 3.1% | -769.69K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -178.02% | -2184.54% | -27.35% | 3.13% | - |
| Operating Expenses | 390.99K | 812.37K | 1.38M | 7.62M | 6.27M | 3.99M | 4.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 162.77K | 426.14K | 943.04K | 5.11M | 4.69M | 2.92M | 3.32M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 228.22K | 386.23K | 438.32K | 2.51M | 1.58M | 1.07M | 739.49K |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -56 |
| Operating Income | -390.99K▲ 0% | -812.37K▼ 107.8% | -1.38M▼ 70.0% | -7.62M▼ 451.5% | -6.27M▲ 17.6% | -4.74M▲ 24.5% | -4.83M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -107.77% | -70.04% | -451.47% | 17.64% | 24.5% | - |
| EBITDA | 0 | -802.86K | -1.35M | -7.01M | -5.5M | -3.99M | -3.98M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -68.76% | -417.63% | 21.52% | 27.49% | 61.91% |
| D&A (Non-Cash Add-back) | 390.99K | 9.52K | 26.46K | 604.4K | 769.69K | 745.59K | 846.32K |
| EBIT | -390.99K | -812.37K | -1.38M | -7.62M | -6.06M | -4.36M | -7.18M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 34.62K | 23.21K | 211.34K | 373.5K | -2.24M |
| Pretax Income | -390.99K▲ 0% | -812.37K▼ 107.8% | -1.35M▼ 65.8% | -7.59M▼ 463.9% | -6.06M▲ 20.2% | -4.36M▲ 28.0% | -4.6M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | -391 | 0 | 0 | 0 | 0 | 0 | -112 |
| Effective Tax Rate % | 0.1% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -390.99K▲ 0% | -812.37K▼ 107.8% | -1.35M▼ 65.8% | -7.42M▼ 451.2% | -5.87M▲ 20.9% | -4.3M▲ 26.7% | -4.5M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -107.77% | -65.78% | -451.16% | 20.9% | 26.73% | 58.43% |
| Net Income (Continuing) | -390.99K | -812.37K | -1.35M | -7.59M | -6.06M | -4.36M | -7.07M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 2M |
| Minority Interest | 0 | 0 | 0 | 15.39K | -40.9K | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.00▼ 112.5% | -0.00▼ 64.7% | -0.02▼ 435.7% | -0.01▲ 20.7% | -0.01▲ 26.9% | -0.35▲ 0% |
| EPS Growth % | - | - | - | - | 20.67% | 26.89% | -565.15% |
| EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.02 | -0.01 | -0.01 | - |
| Diluted Shares Outstanding | 480.4M | 480.4M | 480.4M | 494.49M | 494.49M | 494.49M | 13.01M |
| Basic Shares Outstanding | 480.4M | 480.4M | 480.4M | 494.49M | 494.49M | 494.49M | 13.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
RGC Balance Sheet
Regencell Bioscience Holdings Limited (RGC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 243.31K | 386.98K | 66.85K | 16.44M | 11.62M | 8.11M | 6.59M |
| Cash & Short-Term Investments | 243.31K | 386.98K | 59.41K | 16.42M | 11.56M | 7.96M | 0 |
| Cash Only | 243.31K | 386.98K | 59.41K | 6.42M | 1.56M | 2.96M | 0 |
| Short-Term Investments | 0 | 0 | 0 | 10M | 10M | 5M | 0 |
| Accounts Receivable | 0 | 0 | 7.44K | 27.6K | 56.55K | 152.78K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | -27.6K | -56.55K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | -6.7 |
| Other Current Assets | 0 | 0 | -7.44K | 0 | 0 | 0 | 6.59M |
| Total Non-Current Assets | 0 | 127.04K | 273.29K | 1.57M | 1M | 324.2K | 892.74K |
| Property, Plant & Equipment | 0 | 108.32K | 81.86K | 1.46M | 891.91K | 226.51K | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 18.72K | 191.42K | 114.3K | 108.5K | 97.68K | 1.74M |
| Total Assets | 243.31K▲ 0% | 514.02K▲ 111.3% | 340.13K▼ 33.8% | 18.02M▲ 5197.6% | 12.62M▼ 30.0% | 8.44M▼ 33.1% | 7.48M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 111.26% | -33.83% | 5197.59% | -29.95% | -33.15% | -124.33% |
| Total Current Liabilities | 2.08M | 3.16M | 4.34M | 577.76K | 606.91K | 193.58K | 0 |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 2.08M | 3.07M | 3.68M | 410.99K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | -410.99K | 0 | 0 | 0 |
| Current Ratio | 0.12x | 0.12x | 0.02x | 28.46x | 19.15x | 41.92x | 41.92x |
| Quick Ratio | 0.12x | 0.12x | 0.02x | 28.51x | 19.24x | 41.92x | 41.92x |
| Cash Conversion Cycle | - | - | - | - | - | - | -6.7 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 360.27K | 25.41K | 25.93K | 763.84K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 360.27K | 25.41K | 25.93K | 51.34K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M |
| Total Liabilities | 2.08M | 3.16M | 4.34M | 938.03K | 632.32K | 219.51K | 763.84K |
| Total Debt | 2.08M | 3.07M | 3.68M | 771.25K | 463.67K | 85.74K | 0 |
| Net Debt | 1.84M | 2.68M | 3.62M | -5.65M | -1.1M | -2.88M | 0 |
| Debt / Equity | - | - | - | 0.05x | 0.04x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -1.84M▲ 0% | -2.65M▼ 44.2% | -4M▼ 50.8% | 17.08M▲ 527.3% | 11.99M▼ 29.8% | 8.22M▼ 31.5% | 6.72M▲ 0% |
| Equity Growth % | - | -44.19% | -50.8% | 527.27% | -29.81% | -31.45% | -125.85% |
| Book Value per Share | -0.00 | -0.01 | -0.01 | 0.03 | 0.02 | 0.02 | 0.52 |
| Total Shareholders' Equity | -1.84M | -2.65M | -4M | 17.07M | 12.03M | 8.22M | 6.72M |
| Common Stock | 100 | 100 | 100 | 130 | 130 | 130 | 6.72M |
| Retained Earnings | -1.84M | -2.65M | -4M | -11.44M | -17.32M | -21.62M | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | -86.66K | -45.77K | 0 |
| Minority Interest | 0 | 0 | 0 | 15.39K | -40.9K | 0 | 0 |
RGC Cash Flow Statement
Regencell Bioscience Holdings Limited (RGC) cash flow — operating, investing & free cash flow history
| Line item | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -390.99K | -726.57K | -767.31K | -5.27M | -4.96M | -4M | -4M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -85.83% | -5.61% | -586.43% | 5.77% | 19.37% | 144.51% |
| Net Income | -390.99K | -812.37K | -1.35M | -7.45M | -5.87M | -4.36M | -4.5M |
| Depreciation & Amortization | 0 | 9.52K | 26.46K | 604.4K | 769.69K | 745.59K | 1.13M |
| Stock-Based Compensation | 0 | 0 | 0 | 2.76M | 930K | 449.31K | 914.59K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | -159.34K | -282.56K | -248K | -387.71K |
| Working Capital Changes | 0 | 76.28K | 552.98K | -1.02M | -508.94K | -585.37K | -839.84K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | -117.84K | 0 | -10.78M | 58.98K | 5.24M | 5.27M |
| Capital Expenditures | 0 | -117.84K | 0 | -780.88K | -27.39K | -5.38K | -19.07K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -10M | 86.37K | 0 | 43.19K |
| Cash from Financing | 480.99K | 988.08K | 439.75K | 22.41M | 134.91K | 102.28K | 169.74K |
| Debt Issued (Net) | 480.99K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 988.08K | 439.75K | 22.41M | 134.91K | 102.28K | 169.74K |
| Net Change in Cash | 90K▲ 0% | 143.67K▲ 59.6% | -327.57K▼ 328.0% | 6.36M▲ 2040.9% | -4.85M▼ 176.3% | 1.4M▲ 128.8% | -2.06M▲ 0% |
| Free Cash Flow | -390.99K▲ 0% | -844.41K▼ 116.0% | -767.31K▲ 9.1% | -6.05M▼ 688.2% | -4.99M▲ 17.5% | -4.01M▲ 19.7% | -6.5M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -115.97% | 9.13% | -688.2% | 17.49% | 19.7% | 23.89% |
| FCF per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.89x | 0.57x | 0.71x | 0.85x | 0.93x | 1.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RGC Key Ratios
Regencell Bioscience Holdings Limited (RGC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -113.47% | -40.39% | -42.58% | -67.02% |
| Return on Invested Capital (ROIC) | -3803.35% | - | -103.31% | -42.16% | -43.77% | -43.77% |
| Debt / Equity | - | - | 0.05x | 0.04x | 0.01x | 0.01x |
| FCF Conversion | 0.89x | 0.57x | 0.71x | 0.85x | 0.93x | 1.44x |
| Revenue Growth | - | - | - | - | - | 100% |
RGC Frequently Asked Questions
Regencell Bioscience Holdings Limited (RGC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Regencell Bioscience Holdings Limited (RGC) grew revenue by 0.0% over the past year. Growth has been modest.
Regencell Bioscience Holdings Limited (RGC) reported a net loss of $4.5M for fiscal year 2024.
Dividend & Returns
Regencell Bioscience Holdings Limited (RGC) has a return on equity (ROE) of -42.6%. Negative ROE indicates the company is unprofitable.
Regencell Bioscience Holdings Limited (RGC) had negative free cash flow of $6.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More RGC
Regencell Bioscience Holdings Limited (RGC) financial analysis — history, returns, DCA and operating performance tools
Full RGC Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates